Study to Evaluate the Safety and Tolerability of AD-NP1 in Healthy Human Adult Volunteers

August 12, 2026 updated by: Arjun Deb, MD

A Phase 1 Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety of AD-NP1, a Humanized Monoclonal Antibody Targeting Human ENPP1

This is a Phase 1 single-blind, placebo-controlled, dose-escalation study designed to evaluate the safety of AD-NP1, a humanized monoclonal antibody targeting human ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1). The study aims to assess the maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AD-NP1 in healthy volunteers. Participants will be randomized to receive either AD-NP1 or placebo, with safety and efficacy monitored in accordance with Good Clinical Practice (GCP) guidelines. The study also seeks to explore changes in health-related quality of life (HRQOL) during the trial.

Study Overview

Status

Active, not recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

36

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Los Angeles, California, United States, 90095
        • UCLA Clinical and Translational Research Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Body weight ≤ 90kg
  • Ability to understand and the willingness to sign a written informed consent document
  • Study subject must have read, understood, and provided written informed consent and HIPAA authorization after the nature of the study has been fully explained
  • Be in general good health without history of any of the conditions listed in exclusion criteria
  • No use of any tobacco products for at least 6 months
  • Woman/women of childbearing potential (WOCBP) must agree not to become pregnant from the time of study enrollment until at least 6 months after the completion of the monoclonal antibody infusion. If a WOCBP is sexually active and has no history of hysterectomy or tubal ligation, she must agree to use hormonal or barrier birth control with spermicidal gel
  • Sexually active male subjects must use a barrier method of contraception during the study
  • Screening laboratory values must meet the following criteria:

    • WBC (>3,000 - <11,000/mm^3)
    • Platelets (>100,000/mm^3)
    • Hemoglobin (>10.5 gm/dl)
    • Creatinine (<1.1 x upper limit of normal [ULN])
    • BUN (<1.25 x ULN)
    • AST (<1.1 x ULN)
    • ALT (<1.1 x ULN)
    • Alkaline Phosphatase (<1.1 x ULN)
    • Bilirubin (<1.1 x ULN)
    • Glucose-non-fasting (> 60 mg/dl and < 115 mg/dl)
  • Human immunodeficiency virus (HIV)-infected individuals on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • For subjects with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Individuals with a history of hepatitis C virus (HCV) infection must have been treated and cured. For individuals with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load

Exclusion Criteria:

  • Previous exposure to humanized or human monoclonal antibodies whether FDA approved or investigational
  • Weight > 90 kg
  • History of any of the following illnesses or conditions:
  • a. Respiratory condition (such as asthma requiring daily medication)
  • b. Clinically immunocompromised due to any primary immune or autoimmune deficiency, as a result of chronic disease, cancer or medication used to treat these diseases
  • c. Blood dyscrasias
  • d. Psychiatric disorder that precludes compliance with the clinical protocol
  • e. Hepatitis
  • Any chronic condition requiring daily prescription or over-the-counter medicine except for vitamins and birth control products
  • History of drug or alcohol abuse within previous 12 months or a positive urine toxicology screen within 24 hours of initial screening
  • History of a previous severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis
  • Physical finding on examination considered clinically significant such as heart murmur (other than functional), hepatosplenomegaly, lymphadenopathy, or focal neurological deficit
  • Urinalysis positive for > trace protein, >5 RBC/HPF or >5 WBC/HPF
  • Positive serology for HIV antibody, HCV antibody or Hepatitis B surface antigen
  • Positive serum pregnancy test during screening or positive urine pregnancy test within 24 hours of monoclonal antibody administration, or an unwillingness to undergo pregnancy testing
  • Currently breast-feeding
  • Receipt of an FDA approved vaccine or any investigational study agent within previous 30 days
  • Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the subject participating in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cohort 1 - AD-NP1 (30mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 30 mg/kg
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1. It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
Placebo Comparator: Cohort 1 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 30 mg/kg dose of AD-NP1
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
Experimental: Cohort 2 - AD-NP1 (40 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 40 mg/kg
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1. It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
Placebo Comparator: Cohort 2 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 40 mg/kg dose of AD-NP1
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
Experimental: Cohort 3 - AD-NP1 (60 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 60 mg/kg
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1. It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
Placebo Comparator: Cohort 3 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 60 mg/kg dose of AD-NP1
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
Experimental: Cohort 4 - AD-NP1 (100 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 100 mg/kg
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1. It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
Placebo Comparator: Cohort 4 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 100 mg/kg dose of AD-NP1
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety and tolerability of escalating doses of a single IV dose of AD-NP1
Time Frame: Day of infusion (Day 0) to 28 days post-dose
Assessed by the incidence of treatment-related Adverse Events (AEs) using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Day of infusion (Day 0) to 28 days post-dose

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximum Tolerated Dose of AD-NP1
Time Frame: Day of infusion (Day 0) to 28 days post-dose
To be determined based on dose limiting toxicities (DLTs) and adverse events
Day of infusion (Day 0) to 28 days post-dose
Maximum Plasma Concentration (Cmax) as a pharmacokinetics (PK) parameter
Time Frame: Baseline (pre-dose) up to Day 60 post-dose
Peak plasma concentration obtained directly from the experimental data points, to be measured in Nanograms per milliliter (ng/mL)
Baseline (pre-dose) up to Day 60 post-dose
Time to Maximum Plasma Concentration (Tmax) as a pharmacokinetics (PK) parameter
Time Frame: Baseline (pre-dose) up to Day 60 post-dose
Tmax presents the time at which Cmax is observed, to be measured in hours (h) and minutes (m)
Baseline (pre-dose) up to Day 60 post-dose
Area Under the Plasma Concentration-Time Curve (AUC) as a pharmacokinetics (PK) parameter
Time Frame: Baseline (Pre-dose), 30 minutes, 1, 2, 4, 6 hours, and Days 1, 3, 7, 14, 28, 60 post-dose.
AUC calculated using the linear-log trapezoidal rule from time zero (pre-dose) to the last quantifiable concentration point to be measured in Nanogram x hours per milliliter (ng * h/mL)
Baseline (Pre-dose), 30 minutes, 1, 2, 4, 6 hours, and Days 1, 3, 7, 14, 28, 60 post-dose.
Terminal Elimination Half-life (T(1/2)) as a pharmacokinetics (PK) parameter
Time Frame: Baseline (pre-dose) up to Day 60 post-dose
The rate at which Ad-NP1 is cleared from the systemic plasma circulation, to be measured in Liters per hour (L/h) or Milliliters per minute per kilogram (mL/min/kg)
Baseline (pre-dose) up to Day 60 post-dose
Total Body Clearance (CL) as a pharmacokinetics (PK) parameter
Time Frame: Baseline (pre-dose) up to Day 60 post-dose
The rate at which AD-NP1 is cleared from the systemic plasma circulation, to be measured in Liters per hour (L/h) or Milliliters per minute per kilogram (mL/min/kg)
Baseline (pre-dose) up to Day 60 post-dose
Plasma Uridine Concentration
Time Frame: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma concentrations of uridine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS).
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma Cytidine Concentration
Time Frame: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma concentrations of cytidine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma Orotidine Concentration
Time Frame: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma concentrations of orotidine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma Adenine Concentration
Time Frame: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma concentrations of adenine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma Carbamoyl Aspartate Concentration
Time Frame: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma concentrations of carbamoyl aspartate will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS).
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Immunogenicity of a single IV dose of AD-NP1
Time Frame: Baseline (pre-dose) and Days 1, 7, 14, 28, 90, and 180 post-dose
Determined by measuring levels of circulating anti-drug antibody in blood samples
Baseline (pre-dose) and Days 1, 7, 14, 28, 90, and 180 post-dose
Apparent Volume of Distribution (Vd) as a pharmacokinetics (PK) parameter
Time Frame: Baseline (pre-dose) up to Day 60 post-dose
Volume of distribution calculated during the terminal elimination phase following administration, to be measured in Liters (L) or Liters per kilogram (L/kg)
Baseline (pre-dose) up to Day 60 post-dose

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 2, 2026

Primary Completion (Estimated)

January 1, 2028

Study Completion (Estimated)

May 1, 2028

Study Registration Dates

First Submitted

August 6, 2026

First Submitted That Met QC Criteria

August 6, 2026

First Posted (Actual)

August 13, 2026

Study Record Updates

Last Update Posted (Actual)

August 14, 2026

Last Update Submitted That Met QC Criteria

August 12, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 25-1584
  • PR250528 (Other Grant/Funding Number: DOD-DEPARTMENT OF DEFENSE)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe